Why the study?
Does dalcetrapib reduce the risk of recurrent cardiovascular events in patients with a recent acute coronary syndrome?
Does dalcetrapib reduce the risk of recurrent cardiovascular events in patients with a recent acute coronary syndrome?
Dalcetrapib successfully raises HDL cholesterol but does not translate to a reduction in recurrent cardiovascular events after an acute coronary syndrome.
Clinicians should avoid dalcetrapib for post-ACS secondary prevention; challenges the HDL-raising hypothesis for event reduction.
In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events. (Funded by F. Hoffmann-La Roche; dal-OUTCOMES ClinicalTrials.gov number, NCT00658515.).
No takes yet. Share an insight, caveat, or question.
Schwartz et al. (2012) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: